Teva Pharmaceutical Industries Ltd. $TEVA Position Increased by Assetmark Inc.

Assetmark Inc. raised its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 50.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 55,620 shares of the company’s stock after buying an additional 18,566 shares during the period. Assetmark Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,736,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Grove Bank & Trust raised its position in shares of Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after purchasing an additional 750 shares during the period. Cromwell Holdings LLC raised its holdings in Teva Pharmaceutical Industries by 40.3% during the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after buying an additional 629 shares during the period. Rothschild Investment LLC raised its holdings in Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after buying an additional 1,348 shares during the period. JFS Wealth Advisors LLC lifted its stake in Teva Pharmaceutical Industries by 257.1% during the third quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock valued at $56,000 after buying an additional 2,000 shares in the last quarter. Finally, LRI Investments LLC lifted its stake in Teva Pharmaceutical Industries by 246.0% during the third quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock valued at $57,000 after buying an additional 2,000 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on TEVA shares. The Goldman Sachs Group upped their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Piper Sandler reiterated an “overweight” rating and set a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th. Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Barclays increased their target price on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a report on Friday, January 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.78.

Insider Buying and Selling

In related news, EVP Eliyahu Sharon Kalif sold 345,810 shares of the business’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the transaction, the executive vice president owned 57,478 shares of the company’s stock, valued at approximately $1,933,559.92. The trade was a 85.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Placid Jover sold 14,150 shares of the business’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $448,130.50. Following the transaction, the insider owned 6,774 shares in the company, valued at approximately $214,532.58. The trade was a 67.63% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 920,901 shares of company stock worth $30,056,789. 0.54% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $32.04 on Tuesday. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The stock has a market capitalization of $36.84 billion, a PE ratio of 26.70, a price-to-earnings-growth ratio of 2.83 and a beta of 0.76. Teva Pharmaceutical Industries Ltd. has a 12-month low of $13.04 and a 12-month high of $37.35. The company has a 50 day moving average price of $31.47 and a two-hundred day moving average price of $28.77.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm’s revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.62 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.